Re-appointment of MD and CEO - corrected tenure of 3 years
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.0 pts more than Nifty Microcap 250 and 5.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gujarat Terce Laboratories has issued a corrigendum to its earlier filing dated 29 May 2026. Mr. Aalap Prajapati has been re-appointed as Managing Director and CEO for 3 years (28 October 2026 to 27 October 2029), not 5 years as initially stated. The earlier intimation had an inadvertent error in tenure. Shareholders approved the re-appointment at the 41st AGM on 21 August 2026. Mr. Prajapati has 15+ years of pharma sector experience and is the son of Whole-Time Director Mr. Natwarbhai Prajapati.
Leadership continuity confirmed. Tenure corrected from 5 to 3 years. Promoter family member retained. Correction is administrative, no change in business direction.